Catalyst Wire Dossier Catalyst Wire Dossier

PT027 Budesonide/Albuterol Sulfate MDI

budesonide and albuterol sulfate · AstraZeneca
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PT027 Budesonide/Albuterol Sulfate MDI, covering 2025-08-27 to 2025-08-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma [Phase 3]

See pricing